Core Insights - The article highlights the strategic decision by Yuanqi Forest to split its dairy brand Beihai Pasture from the main group, aiming to focus on its core beverage sector while allowing Beihai Pasture to specialize in the health dairy market [1][3]. Group 1: Strategic Focus - Yuanqi Forest will concentrate resources on core beverage categories such as sparkling water, electrolyte water, and iced tea, while Beihai Pasture will focus on low-temperature yogurt products [3][5]. - The split is seen as a typical practice in the consumer goods industry to "focus on the main track and strengthen productism," reinforcing Yuanqi Forest's core competitiveness after exploring multiple categories [1][5]. Group 2: Development and Innovation - Beihai Pasture aims to innovate around health, committing to developing functional and enjoyable yogurt products to meet consumer demands for healthier dairy options [3][5]. - Yuanqi Forest plans to maintain a humble approach by learning from industry veterans and ensuring product quality through an internal "accompaniment testing" mechanism, where new products are tested by employees before market release [5]. Group 3: Market Position and Growth - Yuanqi Forest's products are now available in over 40 countries, with core products like sparkling water becoming popular among international consumers [5]. - The company expresses confidence in the potential of the Chinese market, believing that more excellent health brands will emerge in the beverage industry [5].

Core Insights - The founder of Yuanqi Forest, Tang Binsen, announced a significant strategic adjustment during the 2025 dealer conference, which involves the separation of the dairy brand Beihai Pasture from the main group to operate independently [1] - Beihai Pasture will focus on low-temperature yogurt and enhance research and development to provide better functional yogurt experiences for consumers [1] - Yuanqi Forest will concentrate its resources on its core beverage categories, including sparkling water, Alien Electrolyte Water, and iced tea, while increasing investment in product development [1] Company Strategy - The decision to split Beihai Pasture is part of Yuanqi Forest's strategy to strengthen its core beverage market competitiveness after exploring multiple product categories [1] - The focus on "focusing on the main track and strengthening productism" is seen as a crucial direction for consumer goods companies to enhance operational certainty [1] - Yuanqi Forest is expected to maintain double-digit growth in 2025, driven by its relentless pursuit of product quality and deep resonance with young consumers regarding health, functionality, and emotional value [1]

Core Insights - The founder of Yuanqi Forest, Tang Binsen, announced a significant strategic adjustment during the 2025 dealer conference, which involves the independent separation of the dairy brand Beihai Pasture from the main group [1] - Beihai Pasture will focus on low-temperature yogurt and enhance research and development to provide better functional yogurt experiences for consumers [1] - Yuanqi Forest will concentrate its resources on core beverage categories such as sparkling water, Alien electrolyte water, and iced tea, while increasing product development investments [1] Company Strategy - The separation of Beihai Pasture is seen as a key step for Yuanqi Forest to strengthen its competitiveness in the core beverage market after exploring multiple product categories [1] - The company aims to enhance operational certainty by focusing on its main beverage track and reinforcing product-centric strategies [1] - Yuanqi Forest is projected to maintain double-digit year-on-year revenue growth in 2025, driven by its relentless pursuit of product quality and deep resonance with young consumers regarding health, functionality, and emotional value [1]

Meeting Overview - The second meeting of the second supervisory board of the company was held on June 9, 2025, with all three supervisors present [2][3]. Resolution Summary - The supervisory board approved the proposal to transfer 100% equity of its wholly-owned subsidiary, Shenzhen Tong'an Pharmaceutical Co., Ltd., to Guangxi Drug Research Institute Co., Ltd. for a price of 15 million yuan [4][10]. - The board concluded that the transaction would enhance asset operation efficiency and is in line with the company's actual situation, with no harm to shareholders' interests [4][10]. Transaction Details - The transaction does not constitute a related party transaction or a major asset restructuring as defined by regulations, and there are no significant legal obstacles to its implementation [8][10]. - The transfer price of 15 million yuan was agreed upon based on voluntary and fair negotiations [14]. Subsidiary Overview - Shenzhen Tong'an Pharmaceutical has not conducted actual business in recent years and primarily holds approval numbers for 20 pharmaceutical products [13]. - The subsidiary's ownership is clear, with no encumbrances or legal issues affecting the transfer [13]. Financial Impact - The sale of the subsidiary is expected to increase the company's profit and cash flow in 2025, aligning with the company's strategic focus on the biopharmaceutical sector [21].